Investigations of ras-related C3 botulinum toxin substrate 1 (RAC1) mutations through in silico approaches revealed that the pathogenic point mutation P29S would facilitate the design of tumour-targeting treatments8. The gene discussed is RAC1; the disease is neoplasm.